title: Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
abstract: This study was designed to investigate the association of HAb18G/CD147 expression and localization with clinicopathological parameters and prognosis in NSCLC. Two hundred and eight (208) specimens of surgically resected NSCLC were stained by immunohistochemistry utilizing mouse anti-human HAb18G/CD147 monoclonal antibody. High levels of HAb18G/CD147 expression were associated with male gender, smoking history, tumor position, distant metastasis status, and clinical stage (p<0.05) in squamous cell carcinoma. In adenocarcinomas, HAb18G/CD147 expression was associated with male gender, tumor diameter, differentiation, lymph node status, distant metastasis status, and clinical stage (p<0.05). HAb18G/CD147 expression with higher PU was predominantly localized in the tumor cell membranes rather than in cytoplasms. In squamous cell carcinomas, membranous localization of HAb18G/CD147 was linked to distant metastasis status and TNM stage (p<0.05). Cytoplasmic localization of HAb18G/CD147 was associated with male gender and smoking history. In adenocarcinomas, membranous localization of HAb18G/CD147 correlated with tumor diameter, differentiation and distant metastasis (p<0.05). Univariate analysis indicated that patients with high HAb18G/CD147 expression and membranous localization predicted poor prognosis in both squamous cell carcinomas and adenocarcinomas. Multivariate analysis showed that lymph node status (HR=1.762, 95%CI 1.105-2.811, p=0.017), distant metastasis status (HR=3.789, 95%CI 2.196-6.539, p=0.000), expression (HR=6.632, 95%CI 2.457-17.904, p=0.000), and localization (HR=0.520, 95%CI 0.341-0.794, p=0.002) were good or excellent independent predictors of patient survival. HAb18G/CD147 is a biomarker characterizing progression and survival of NSCLC. More importantly, its cellular localizations should be considered in the analysis of clinicopathological characteristics and prognostic factors in NSCLC.
authors.affiliation: Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Xu
authors.forename: Ni
authors.initials: N
authors.lastname: Lin
authors.forename: Yu-mei
authors.initials: YM
authors.lastname: Li
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhi
authors.forename: Hong
authors.initials: H
authors.lastname: Shen
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D051926:Basigin / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000401:mortality / Q000556:secondary; D016009:Chi-Square Distribution; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012307:Risk Factors; D013997:Time Factors; D047368:Tumor Burden
chemical_list: C497886:BSG protein, human; D014408:Biomarkers, Tumor; D051926:Basigin